Bacillus Calmette-Guerin BCG — knowledge graph · CancerIndex

Knowledge graph · Drug

Bacillus Calmette-Guerin BCG

Identifier: CI-DRUG-00000682
Entity page: /drug/bacillus-calmette-guerin-bcg ↗
Edges: 14

Neighbours: 4 cancers9 trials1 approvals
Drawn: 14 of 14 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Bacillus Calmette-Guerin BCG approved for …APPROVED_FORderived1 of 1
→ approved for	Health Canada · CA · 1990Marketed in Canada as BCG THERAPEUTIC (DIN 00884308) under ATC L03AX03 BCG VACCINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. Health Canada (CA) · withdrawn · 1990-12-31 · Marketed in Canada as BCG THERAPEUTIC (DIN 00884308) under ATC L03AX03 BCG VACCINE. Indications are not published in the Drug Product Datab…	—	withdrawn	not mapped	1	Regulatory	health-canada-dpd	open ↗

Bacillus Calmette-Guerin BCG studied in …STUDIED_INderived9 of 9
→ studied in	NCT04179162Phase 1/Phase 2 · active not recruiting Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment · 9 trials list this drug (4 active)	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03504163Phase 2 · active not recruiting Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)] · 9 trials list this drug (4 active)	—	—	Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03317158Phase 1/Phase 2 · active not recruiting Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder · 9 trials list this drug (4 active)	—	—	Urothelial Carcinoma,Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03528694Phase 3 · active not recruiting Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer · 9 trials list this drug (4 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT04149574Phase 3 · terminated A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) · 9 trials list this drug (4 active)	—	—	Bladder Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06767982Phase 4 · completed Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC) · 9 trials list this drug (4 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT02281383Phase 2 · completed Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer · 9 trials list this drug (4 active)	—	—	Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02326168early Phase 1 · completed PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer · 9 trials list this drug (4 active)	—	—	Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT00974818Phase 3 · terminated Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients · 9 trials list this drug (4 active)	—	—	Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →